151 related articles for article (PubMed ID: 32850404)
21. Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma?
He Y; Guo T; Wang J; Sun Y; Guan H; Wu S; Peng X
Ann Transl Med; 2019 Mar; 7(5):104. PubMed ID: 31019954
[TBL] [Abstract][Full Text] [Related]
22. Management of first-line palliative chemotherapy for post-treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: Gemcitabine plus cisplatin and non-gemcitabine plus cisplatin chemotherapy.
Yang ZC; Du CC; Liu T; Liu LT; Chen QY; Guo SS; Mai HQ
Head Neck; 2022 Jan; 44(1):113-121. PubMed ID: 34716739
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy with different dose regimens of docetaxel, cisplatin and fluorouracil (TPF) for locoregionally advanced nasopharyngeal carcinoma: a retrospective study.
Jin T; Zhang Q; Jiang F; Qin WF; Jin QF; Cao CN; Piao YF; Feng XL; Luo W; Chen XZ
Oncotarget; 2017 Nov; 8(59):100764-100772. PubMed ID: 29246020
[TBL] [Abstract][Full Text] [Related]
24. Concurrent Chemoradiotherapy with Docetaxel, Cisplatin and 5-Fluorouracil (TPF) in Patients with Nasopharyngeal Carcinoma.
Komatsu M; Arai Y; Yabuki K; Sano D; Shiono O; Sakuma Y; Nishimura G; Takahashi M; Taguchi T; Oridate N
Anticancer Res; 2015 Dec; 35(12):6861-7. PubMed ID: 26637908
[TBL] [Abstract][Full Text] [Related]
25. Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
Liao JF; Zhang Q; Du XJ; Lan M; Liu S; Xia YF; Cai XY; Luo W
Cancer Commun (Lond); 2019 Jun; 39(1):40. PubMed ID: 31248459
[TBL] [Abstract][Full Text] [Related]
26. A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Chen J; Qi J; Yu B; Peng XH; Wang F; Tan JJ; Chen QQ; Peng XY; Zeng FF; Liu X
Med Sci Monit; 2018 Apr; 24():2562-2568. PubMed ID: 29697098
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).
Frikha M; Auperin A; Tao Y; Elloumi F; Toumi N; Blanchard P; Lang P; Sun S; Racadot S; Thariat J; Alfonsi M; Tuchais C; Cornely A; Moussa A; Guigay J; Daoud J; Bourhis J;
Ann Oncol; 2018 Mar; 29(3):731-736. PubMed ID: 29236943
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.
Jin T; Qin WF; Jiang F; Jin QF; Wei QC; Jia YS; Sun XN; Li WF; Chen XZ
Transl Oncol; 2019 Apr; 12(4):633-639. PubMed ID: 30797141
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Teo M; Karakaya E; Young CA; Dyker KE; Coyle C; Sen M; Prestwich RJ
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):647-53. PubMed ID: 23948462
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
34. A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery.
Wang Y; Wang ZQ; Jiang YX; Wang FH; Luo HY; Liang Y; Wang DS; Li YH
Expert Opin Pharmacother; 2016 Aug; 17(12):1585-90. PubMed ID: 27328125
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI;
N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013
[TBL] [Abstract][Full Text] [Related]
36. Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil.
Liang Y; Bu JG; Cheng JL; Gao WW; Xu YC; Feng J; Chen BY; Liang WC; Chen KQ
Asian Pac J Cancer Prev; 2015; 16(14):6011-7. PubMed ID: 26320489
[TBL] [Abstract][Full Text] [Related]
37. Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.
Ou D; Blanchard P; El Khoury C; De Felice F; Even C; Levy A; Nguyen F; Janot F; Gorphe P; Deutsch E; Temam S; Tao Y
Oral Oncol; 2016 Nov; 62():114-121. PubMed ID: 27865364
[TBL] [Abstract][Full Text] [Related]
38. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
Zhou J; Zhang WM; Chen H; Xie B; Zheng JH; Xu ZY; Lin JR
Zhonghua Zhong Liu Za Zhi; 2009 Nov; 31(11):867-72. PubMed ID: 20137355
[TBL] [Abstract][Full Text] [Related]
40. Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults: Results from a nonendemic region.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Lokanatha D; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2018; 55(3):257-260. PubMed ID: 30693890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
